THE JOURNAL OF SCHOOL AND UNIVERSITY MEDICINE - Volume 5 Issue 4, October 2018

Pages: 23-26

Date of Publication: 31-Oct-2018

Print Article   Download XML  Download PDF

Management of the extraintestinal manifestations in Crohn disease

Author: Olteanu Ovidiu Andrei, Radu Cristina, Grigorescu Raluca

Category: Medical

Abstract:

In developing countries the incidence of inflammatory bowel disease is increasing. Crohn's disease is characterized by transmural inflammation that can affect the digestive tract at any level and may have numerous extraintestinal manifestations that affect the quality of life of the patient. We will present a patient with pancolonic Crohn's disease treated by progressive escalation of therapeutic options until administration of biological treatment. During therapy with recombinant human monoclonal antibodies in classical doses, the patient presented incomplete control of the bowel disease and developed psoriasis, a condition whose management is still incompletely elucidated by experts.

Keywords: Crohn's disease, young, extraintestinal manifestations

References:

1.Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug 8;347(6):417-29

2.Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991 Feb;100(2):350-8

3.Pariente B, Cosnes J, Danese S et al. Development of the Crohn’s disease digestive damage score, the Lemann score. Inflamm Bowel Dis. 2011;17:1415–1422

4.Edward V, Loftus Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences Gastroenterology May 2004;126(6):1504–1517

5.Peyrin-Biroulet L, Loftus EV Jr, Colombel JF et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 2010;105:289–297

6.Peyrin-Biroulet L, Loftus EJ, Colombel J et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm Bowel Dis. 2011;17:471–478.

7.Estimates of TB and MDR-TB burden are produced by WHO in consultation with contries. Generated : 2018-09-30

8.Annunziata M, Caviglia R, Papparella L et al. Upper gastrointestinal involvement of Crohn’s disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci. 2012;57:1618–1623

9.Thomsen OO, Cortot A, Jewell D et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339:370–374

10.Yang YX, Lichtenstein GR. Corticosteroids in Crohn’s disease. Am J Gastroenterol 2002;97:803–823

11.Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2013;(4):CD000545

12.Hazlewood GS, Rezaie A, Borman M et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology 2015;148:344–354.e5 quiz e14-5

13. Fiorino G, Omodei P. Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin?, Journal of Crohn's and Colitis 2015;9(9):697–698

14.Ko JM, Gottlieb AB, Kerbleski JF. Induction and exarcerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100–108

15. Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNFa therapy for inflamatory bowel disease: A systemic literature review based on 222 cases. J Crohns Colitis. 2013;7:517–524